Update: March 23, 2020
Replicel just published a slightly encouraging update (h/t “Bekoo”). Well known dermatologist Dr. Jerry Shapiro has high praise for the recent Shiseido trial in Japan. He makes an astute point that most of the patients in the trial were at advanced stages of hair loss. This makes the results even more encouraging for those with recent hair loss. For transparency, the update does mention that Dr. Shapiro was a founding shareholder of Replicel.
The autologous cell-based therapy with dermal sheath cup cells that was used in the Shiseido study is the same product that RepliCel refers to as RCH-01:
Shiseido has licensed the co-development and commercial rights in Asia. RepliCel maintains the complete and unrestricted rights to this product outside of Asia.
Also of interest and something that I missed before: the Shiseido trial proved that the RCH-01 dermal sheath cup cell product can be used after cryopreservation and thawing.
March 11, 2020
In my last post on Shiseido, someone pointed out that Replicel has updated its Twitter feed. It seems like the latest Shiseido trials used Replicel’s RCH-01 technology. A bit strange that Shiseido does not mention Replicel in its latest communications. Perhaps indicating that the two companies’ partnership issues are not yet close to being resolved.
Yesterday, Replicel also got good news from the Japanese regulatory agency PMDA. This was in regards to the issuance of several non-hair loss product related patents. And Replicel got a final consultation go-ahead today regarding the company’s skin and tendon regeneration products.
Replicel’s stock price is even more volatile than usual this week. It dropped 33 percent on Monday. Then increased 71 percent on Tuesday. Down 10 percent so far today.
Replicel Stock Price
May 26, 2019
For those who are in the finance sector, why has Replicel’s stock price declined so drastically and continuously during the past five years? Earlier today, the company made yet another positive press release. This time regarding its YOFOTO licensee in China and its decent growth prospects.
This comes on top of the two announcements that they already made earlier this month. I covered those in my post on Shiseido and Replicel. If any of this blog’s readers is investing in REPCF stock, please update us regularly on any developments. Including insider transactions, earnings announcements, P/E ratios and more.